Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination

Clinical Cancer Research

Volumn 5, Issue 5, 1999, Pages 1173-1182

  Maitre, Nathalie ^a   Brown, Jason M ^a   Demcheva, Marina ^b   Kelley, Joseph R ^a   Lockett, Mark A ^a   Vournakis, John ^b   Cole, David J ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CYTOKINE; GAMMA INTERFERON; N ACETYLGLUCOSAMINE; POLYPEPTIDE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD; ANTIGENS, CD86; ANTIGENS, NEOPLASM; CANCER VACCINES; CYTOTOXICITY TESTS, IMMUNOLOGIC; EPITOPES; FEMALE; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; OVALBUMIN; PEPTIDE FRAGMENTS; RECEPTORS, INTERLEUKIN-2; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; THYMOMA; THYMUS NEOPLASMS; VACCINATION;

EID: 0032925624     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., Simpson, C., Carter, C., Bock, S., Schwartzentruber, D., Wei, J. P., and White, D. E. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N. Engl. J. Med., 319: 1676-1680, 1988.
2. Rosenberg, S. A. The development of new cancer therapies based on the molecular identification of cancer regression antigens. Cancer J. Sci. Am., 1: 90-100, 1995.
3. Rosenberg, S. A. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today, 18: 175-182, 1997.
4. Rosenberg, S. A., Spiess, P., and Lafreniere, R. A. A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science (Washington DC), 233: 1318-1321, 1986.
5. Kawakami, Y., Eliyahu, S., Sakaguchi, K., Robbins, P. F., Rivoltini, L., Yannelli, J. R., Appella, E., and Rosenberg, S. A. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med., 180: 347-352, 1992.
6. Kawakami, Y, Eliyahu, S., Delgado, C. H., Robbins, P. F., Sakaguchi, K., Appella, E., Yannelli, J. R., Adema, G. J., Miki, T., and Rosenberg, S. A. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA, 91: 6458-6462, 1994.
7. Topalian, S. L., Solomon, D., and Rosenberg, S. A. Tumor specific cytolysis by lymphocytes infiltrating human melanomas. J. Immunol., 142: 3714-3724, 1989.
8. Darrow, T. L., Slingluff, C. L. J., and Siegler, H. F. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes: evidence for shared tumor-antigens. J. Immunol., 142: 3329-3335, 1989.
9. Wang, R. F., Robbins, P. F., Kawakami, Y., Kang, X. Q., and Rosenberg, S. A. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J. Exp. Med., 181: 799-804, 1995.
10. Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. R., Rivoltini, L., Topalian, S. L., Miki, T., and Rosenberg, S. A. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA, 91: 3515-3519, 1994.
11. van der Bruggen, P., Szikora, J. P., Boel, P., Wildmann, C., Somville, M., Sensi, M., and Boon, T. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601*. Eur. J. Immunol., 24: 2134-2140, 1994.
12. Cox, A. L., Skipper, J., Chen, Y., Henderson, R. A., Darrow, T. L., Shabanowitz, J., Engelhard, V. H., Hunt, D. F., and Slingluff, C. L. J. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science (Washington DC), 204: 716-719, 1994.
13. Robbins, P. F., El-Gamil, M., Kawakami, Y. F., Loftus, D., Appella, E., and Rosenberg, S. A. A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med., 183: 1185-1192, 1996.
14. Cole, D. J., Weil, D. P., Shamamian, P., Rivoltini, L., Kawakami, Y., Topalian, S., Jennings, C., Eliyahu, S., Rosenberg, S. A., and Nishimura, M. I. Identification of MART-1-specific T-cell receptors: T cells using distinct T-cell receptor variable and joining regions recognize the same tumor epitope. Cancer Res., 54: 5265-5268, 1994.
15. Cole, D. J., Weil, D. P., Shilyansky, J., Custer, M., Kawakami, Y., Rosenberg, S. A., and Nishimura, M. I. Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen. Cancer Res., 55: 748-752, 1995.
16. Van der Bruggen, P., Traversari, P. C., Chomez, P., Lurquin, C., DePlaen, E., Van den Eynde, B., Knuth, A., and Boon, T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (Washington DC), 254: 1643-1647, 1991.
17. Rock, K. L., Rothstein, L., Gamble, S., and Fleischacker, C. Characterization of antigen-presenting cells that present exogenous antigens in association with class I MHC molecules. J. Immunol., 150: 438-446, 1993.
18. Mandelboim, O., Berke, G., Fridkin, M., Feldman, M., Eisenstein, M., and Eisenbach, L. CTL induction by a tumor-associated antigen octapeptide derived from a murine lung carcinoma. Nature (Lond.), 369: 67-71, 1994.
19. Mandelboim, O., Vadai, E., Fridkin, M., Katz-Killel, A., Feldman, M., Berke, G., and Eisenbach, L. Regression of established murine carcinoma metastases following vaccination with tumor-associated antigen peptides. Nat. Med., 1: 1179-1183, 1995.
20. Zhou, F., Rouse, B. T., and Huang, L. Prolonged survival of thymoma-bearing mice after vaccination with a soluble protein antigen entrapped in liposomes: a model study. Cancer Res., 52: 6287-6291, 1992.
21. Raychaudhuri, S., Tonks, M., Carbone, F., Ryskamp, T., Morrow, W. J. W., and Hanna, N. Induction of antigen-specific class-I restricted cytotoxic T cells by soluble proteins in vivo. Proc. Natl. Acad. Sci. USA., 89: 8308-8312, 1992.
22. Porgador, A., Staats, H. F., Faiola, B., Gilboa, E., and Palker, T. J. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo. J. Immunol., 158: 834-841, 1997.
23. Newman, M. J., Wu, J., Gardner, B. H., Munroe, K. J., Leombruno, D., Recchia, J., Kensil, C. R., and Coughlin, R. T. Saponin adjuvant induction of ovalbumin-specific CD8+cytotoxic T lymphocyte responses. J. Immunol., 148: 2357-2362, 1992.
24. Mukherji, B., Chakraborty, N. G., Yamasaki, S., Okino, T., Yamase, H., Sporn, J. R., Kurtzman, S. K., Ergin, M. T., Ozols, J., Meehan, J., and Mauri, F. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Natl. Acad. Sci. USA., 92: 8078-8082, 1995.
25. McCabe, B. J., Irvine, K. R., Nishimura, M. I., Yang, J. C., Spiess, P. J., Shulman, E. P., Rosenberg, S. A., and Restifo, N. P. Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses. Cancer Res., 55: 1741-1747, 1995.
26. Zhai, Y., Yang, J. C., Kawakami, Y., Spiess, P., Wadsworth, S. C., Cardoza, L. M., Coutre, L. A., Smith, A. E., and Rosenberg, S. A. Antigen-specific tumor vaccines, development and characterization of recombinant adenoviruses encoding MART-1 or gp100 for cancer therapy. J. Immunol., 156: 700-710, 1996.
27. Bellone, M., Iezzi, G., Martin-Fontecha, A., Rivolta, L., Manfredi, A. A., Protti, M. P., Freschi, M., Dellabona, P., Casorati, G., and Rugarli, C. Rejection of nonimmunogenic melanoma by vaccination with natural melanoma peptides on engineered antigen-presenting cells. J. Immunol., 158: 783-789, 1997.
28. Nair, S. K., Boczkowski, D., Snyder, D., and Gilboa, E. Antigen-presenting cells pulsed with unfractionated tumor derived peptides are potent tumor vaccines. Eur. J. Immunol., 27: 589-597, 1997.
29. + T-cell responses and prolongs survival of thymoma-bearing mice. Cancer Res., 54: 4155-4161, 1994.
30. Porgador, A., Iwasaki, A., Barber, B. H., Restifo, N.P., and Germain, R. N. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J. Exp. Med., 188: 1075-1082, 1998.
31. Surman, D. R., Irvine, K. R., Shulman, E. P., Allweis, T. M., Rosenberg, S. A., and Restifo, N. P. Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization. J. Immunol. Methods, 214: 51-62, 1998.
32. Schmidt, W., Steinlein, P., Buschle, M., Schweighoffer, T., Herbst, E., Mechtler, K., Kirlappos, H., and Birnstiel, M. L. Transloading of tumor cells with foreign major histocompatibility complex class I peptide ligand: a novel general strategy for the generation of potent cancer vaccines. Proc. Natl. Acad. Sci. USA., 93: 9759-9763, 1996.
33. Zhou, F. T., Rouse, B. T., and Huang, L. Induction of cytotoxic T lymphocytes in vivo with protein antigen entrapped in membranous vehicles. J. Immunol., 149: 1599-1604, 1992.
34. Toes, R. E. M., Blom, R. J. J., Offringa, R., Kast, W. M., and Melief, C. J. M. Enhanced tumor outgrowth after peptide vaccination, functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J. Immunol., 156: 3911-3918, 1996.
35. Aichele, P., Brduscha-Riem, K., Zinkernagel, R. M., Hengartner, H., and Pircher, H. T cell priming versus T cell tolerance induced by synthetic peptides, J. Exp. Med., 182: 261-266, 1995.
36. Moore, M. W., Carbone, F. R., and Bevan, M. J. Introduction of soluble antigen into the class I pathway of antigen processing and presentation. Cell, 54: 777-785, 1988.
37. Rotzschke, O., Falk, K., Stevanovic, S., Jung, G., Walden, P., and Rammensee, H-G. Exact prediction of a natural T cell epitope. Eur. J. Immunol., 21: 2891-2894, 1991.
38. Shastri, N., and Gonzalez, F. Endogenous generation and presentation of the ovalbumin peptide/Kb complex to T cells. J. Immunol., 150: 2724-2736, 1993.
39. Brichard, V., Van Pel, W., Wolfel, T., DePlaen, E., Lethe, B., Coulie, P., and Boon, T. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med., 178: 489-495, 1993.
40. Cole, D. J., Gattoni-Celli, S., McClay, E. F., Metcalf, J. S., Brown, J. M., Nabavi, N., Newton, D. A., III, Woolhiser, C. B., Wilson, M. C., and Vournakis, J. N. Characterization of a sustained-release delivery system for combined cytokine/peptide vaccination using a poly-N-acetyl glucosamine-based polymer matrix. Clin Cancer Res., 3: 867-873, 1997.
41. Gaugler, B., Van den Eynde, B., Van der Bruggen, P., Romero, P., Gaforio, J. J., De Plaen, E., Lethe, B., Brasseur, F., and Boon, T. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med., 179: 921-930, 1994.
42. Traversari, C., Van der Bruggen, P., Luescher, I. F., Lurquin, C., Chomez, P., Van Pel, A., De Plaen, E., Amar-Costesec, A., and Boon, T. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 cytolytic lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med., 176: 1453-1456, 1994.
43. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwartz, S. E., Spiess, P. J., Wunderlich, J. R., Parkhurst, M. R., Kawakami, Y., Seipp, C. A., Einhorn, J. H., and White, D. E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med., 4: 321-327, 1998.
44. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R. C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating stimulated potent, specific and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA, 90: 32539-32543, 1993.
45. Feldkamp, M., Vreugdenhil, G. R., Vierboom, M. P., Ras, E., van der Burg, S., ter Schegget, J., Melief, C. J., and Kast, W. M. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16 induced tumors. Eur. J. Immunol., 25: 2638-2642, 1995.
46. Gansbacher, B., Bannerji, R., Daniels, B., Zier, K., Cronin, K., and Gilboa, E. Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res., 50: 7820-7825, 1990.
47. Colombo, M. P., Vagliana, M., Spreafico, F., Parenza, M., Chiodoni, C., Melani, C., and Stoppacciaro, A. Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res., 56: 2531-2534, 1996.
48. Nastala, C. L., Edington, H. D., McKinney, T. G., Tahara, T. G., Nalesnik, M. A., Brunda, M. J., Gately, M. K., Wolf, S. F., Schreiber, R. D., Storkus, W. J., and Lotze, M. T. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol., 153: 1697-1706, 1994.
49. Sanda, M. G., Ayyagari, S. R., Jaffee, E. M., Epstein, J. I., Clift, S. L., Cohen, L., Dranoff, G., Pardoll, D. M., Mulligan, R. C., and Simons, J. W. Demonstration of a rational strategy for human prostate cancer gene therapy. J. Urol., 151: 622-628, 1994.
50. Melief, C., and Kast, M. T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T-lymphocytes and by vaccination with minimal essential epitopes. Immunol. Rev., 146: 167-177, 1995.
51. Schorich, G. F. M., Malissen, M., Schmitt-Verhuylts, A., Malissen, B., Hammerling, G. J., and Arnold, B. Distinct mechanisms of extrathymic T-cell tolerance due to differential expression of self-antigen. Int. Immunol. 4: 581-590, 1992.
52. Roitt, I., Brostoff, J., and Male, D. Immunology, Ed. 3. London: Mosby-Year Book Europe Limited, 1993.
53. Kuby, J. Immunology, Ed. 2, p. 660. New York: W. H. Freeman and Company, 1994.
54. Alters, S. E., Gadea, J. R., Sorich, M., O'Donoghue, G., Talib, S., and Philip, R. Dendritic cells pulsed with CEA Induce CEA-specific CTL with restricted TCR repertoire. J. Immunother., 21: 17-26, 1998.
55. Wong, C., Morse, M., and Nair, S. M. Induction of primary, human antigen specific cytotoxic T lymphocytes in vitro using dendritic cells pulsed with peptides. J. Immunother., 21: 32-40, 1998.
56. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., and Schadendorf, D. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat. Med., 4: 328-335, 1998.
57. Apostolopoulos, V., Osinski, C., and McKenzie, I. F. C. MUC1-cross reactive Galα(1,3)Gal antibodies in humans switch immune responses from cellular to humoral. Nat. Med., 4: 315-320, 1998.